...it does go on quite frequently. This occurs not only with differential dosing of a drug but where also a drug has more than one indication and the drugs are then differentially priced. An example that springs to mind is the alpha-reductase inhibitor (ARI) finasteride marketed as proscar for benign prostatic hyperplasia (BPH), and propecia for alopecia. This may have been documented.
Safety issues are associated specifically with the individual drug, however, the regulatory authorities consider carefully any drug where the differential indication/pricing issue occurs.
You can buy pill cutters specifically for the purpose you describe.
Warm wishes, Craig
> Craig Currie Ph.D.
> Manager- GI & Metabolic Diseases
> Global Health Outcomes
> GlaxoWellcome
> Greenford
> London UB6 OHE
> Tel: 44 (0) 208 9662800 (Direct)/ 9662206 (Secretary [Rhoda Luer])
> Fax: 44 (0) 208 9662193
> Email: [log in to unmask]
>
> -----Original Message-----
> From: Adams, Elizabeth [SMTP:[log in to unmask]]
> Sent: Tuesday, January 11, 2000 3:16 PM
> To: 'INAHTA listserv'; [log in to unmask]
> Subject: evidence on pill splitting
>
> Dear colleague,
>
> Is anyone aware of evidence for increased risk or reduced safety from pill
> splitting (halving a pill or tablet)? I am particularly concerned with the
> differences between scored vs. non-scored pills in accuracy of dosing,
> absorption, assessing patients' ability to split, etc.
>
> I look forward to your comments. Thank you in advance.
>
> Liz Adams
> Management and Program Analyst
> VA Technology Assessment Program
> 150 S. Huntington Ave. Bldg 4 (152M)
> Boston, MA 02130
> Tel. (617) 278-4469 Fax (617) 278-4438
> [log in to unmask] <mailto:[log in to unmask]>
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|